349 related articles for article (PubMed ID: 8743334)
1. Clinical pharmacokinetics of therapeutic bile acids.
Crosignani A; Setchell KD; Invernizzi P; Larghi A; Rodrigues CM; Podda M
Clin Pharmacokinet; 1996 May; 30(5):333-58. PubMed ID: 8743334
[TBL] [Abstract][Full Text] [Related]
2. Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health.
Dilger K; Hohenester S; Winkler-Budenhofer U; Bastiaansen BA; Schaap FG; Rust C; Beuers U
J Hepatol; 2012 Jul; 57(1):133-40. PubMed ID: 22414767
[TBL] [Abstract][Full Text] [Related]
3. Influence of cholestasis on absorption of ursodeoxycholic acid.
Sauer P; Benz C; Rudolph G; Klöters-Plachky P; Stremmel W; Stiehl A
Dig Dis Sci; 1999 Apr; 44(4):817-22. PubMed ID: 10219843
[TBL] [Abstract][Full Text] [Related]
4. Pharmacology of ursodeoxycholic acid, an enterohepatic drug.
Hofmann AF
Scand J Gastroenterol Suppl; 1994; 204():1-15. PubMed ID: 7824870
[TBL] [Abstract][Full Text] [Related]
5. Comparative studies of metabolism of simultaneously administered chenodeoxycholic acid and ursodeoxycholic acid in hamsters.
Kihira K; Yamauchi T; Kuramoto T; Une M; Yoshii M; Hoshita T
Steroids; 1994 Jul; 59(7):431-5. PubMed ID: 7974527
[TBL] [Abstract][Full Text] [Related]
6. Competition in liver transport between chenodeoxycholic acid and ursodeoxycholic acid as a mechanism for ursodeoxycholic acid and its amidates' protection of liver damage induced by chenodeoxycholic acid.
Piazza F; Montagnani M; Russo C; Azzaroli F; Aldini R; Roda E; Roda A
Dig Liver Dis; 2000 May; 32(4):318-28. PubMed ID: 11515630
[TBL] [Abstract][Full Text] [Related]
7. Metabolism of sulfonate analogs of ursodeoxycholic acid and their effects on biliary bile acid composition in hamsters.
Mikami T; Kihira K; Ikawa S; Yoshii M; Miki S; Mosbach EH; Hoshita T
J Lipid Res; 1993 Mar; 34(3):429-35. PubMed ID: 8468526
[TBL] [Abstract][Full Text] [Related]
8. Serum bile acids and ursodeoxycholic acid treatment in cystic fibrosis-related liver disease.
O'Brien SM; Campbell GR; Burke AF; Maguire OC; Rowlands BJ; FitzGerald MX; Hegarty JE
Eur J Gastroenterol Hepatol; 1996 May; 8(5):477-83. PubMed ID: 8804877
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive study of the biliary bile acid composition of patients with cystic fibrosis and associated liver disease before and after UDCA administration.
Nakagawa M; Colombo C; Setchell KD
Hepatology; 1990 Aug; 12(2):322-34. PubMed ID: 2391071
[TBL] [Abstract][Full Text] [Related]
10. The continuing importance of bile acids in liver and intestinal disease.
Hofmann AF
Arch Intern Med; 1999 Dec 13-27; 159(22):2647-58. PubMed ID: 10597755
[TBL] [Abstract][Full Text] [Related]
11. Intestinal absorption of the bile acid analogue 75Se-homocholic acid-taurine is increased in primary biliary cirrhosis, and reverts to normal during ursodeoxycholic acid administration.
Lanzini A; De Tavonatti MG; Panarotto B; Scalia S; Mora A; Benini F; Baisini O; Lanzarotto F
Gut; 2003 Sep; 52(9):1371-5. PubMed ID: 12912872
[TBL] [Abstract][Full Text] [Related]
12. Bile acid conjugation in early stage cholestatic liver disease before and during treatment with ursodeoxycholic acid.
Fracchia M; Setchell KD; Crosignani A; Podda M; O'Connell N; Ferraris R; Hofmann AF; Galatola G
Clin Chim Acta; 1996 Apr; 248(2):175-85. PubMed ID: 8740581
[TBL] [Abstract][Full Text] [Related]
13. Intestinal absorption and biliary secretion of ursodeoxycholic acid and its taurine conjugate.
Rudolph G; Kloeters-Plachky P; Sauer P; Stiehl A
Eur J Clin Invest; 2002 Aug; 32(8):575-80. PubMed ID: 12190957
[TBL] [Abstract][Full Text] [Related]
14. Intestinal absorption of bile acids: effect of ursodeoxycholic acid treatment.
Stiehl A
Ital J Gastroenterol; 1995 May; 27(4):193-5. PubMed ID: 8520037
[TBL] [Abstract][Full Text] [Related]
15. Abnormal hepatic sinusoidal bile acid transport in an Amish kindred is not linked to FIC1 and is improved by ursodiol.
Morton DH; Salen G; Batta AK; Shefer S; Tint GS; Belchis D; Shneider B; Puffenberger E; Bull L; Knisely AS
Gastroenterology; 2000 Jul; 119(1):188-95. PubMed ID: 10889168
[TBL] [Abstract][Full Text] [Related]
16. Delta 4-3-oxosteroid 5 beta-reductase deficiency: failure of ursodeoxycholic acid treatment and response to chenodeoxycholic acid plus cholic acid.
Clayton PT; Mills KA; Johnson AW; Barabino A; Marazzi MG
Gut; 1996 Apr; 38(4):623-8. PubMed ID: 8707100
[TBL] [Abstract][Full Text] [Related]
17. New therapeutical indications of ursodeoxycholic acid.
Copaci I; Micu L; Iliescu L; Voiculescu M
Rom J Gastroenterol; 2005 Sep; 14(3):259-66. PubMed ID: 16200237
[TBL] [Abstract][Full Text] [Related]
18. Radiosynthesis of N-¹¹C-Methyl-Taurine-Conjugated Bile Acids and Biodistribution Studies in Pigs by PET/CT.
Schacht AC; Sørensen M; Munk OL; Frisch K
J Nucl Med; 2016 Apr; 57(4):628-33. PubMed ID: 26697965
[TBL] [Abstract][Full Text] [Related]
19. Bile acid N-acetylglucosaminidation. In vivo and in vitro evidence for a selective conjugation reaction of 7 beta-hydroxylated bile acids in humans.
Marschall HU; Matern H; Wietholtz H; Egestad B; Matern S; Sjövall J
J Clin Invest; 1992 Jun; 89(6):1981-7. PubMed ID: 1602004
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
